On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The Food and Drug Administration’s (FDA) recent authorization of FluMist for at-home administration marks the beginning of a new chapter in vaccine access and delivery. Before now, self ...

Now that the U.S. Food and Drug Administration has approved the at-home use of the flu vaccine spray FluMist, how do you know that it's the right choice for you and your family? One expert offers ...

SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has approved the at-home use of ...

FluMist, the nasal flu vaccine spray, was approved in September by the U.S. Food and Drug Administration for at-home use starting in fall 2025. Currently, it can only be administered by a healthcare ...

What You Need to Know About FluMist, the Nasal Flu Vaccine By Robin Foster HealthDay Reporter SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now By Robin Foster HealthDay Reporter TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making ...

The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list.

Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market. But when the drug was declared to be in shortage in December that same ...

As AI technology evolves rapidly, the FDA is tackling the challenge of balancing innovation with patient safety, shaping regulations that ensure AI tools remain effective throughout their entire ...